Abbott: net income fell 44% in third-quarter 2026
Abbott Laboratories reported third-quarter 2026 revenue of $13.0 billion, up 14.5% year-over-year. Amid rising operating expenses and the integration of Exact Sciences, acquired in March 2026, Abbott’s net income fell 44% to $920 million.
Key points
- Abbott grew revenue in the third quarter of 2026 alongside rising operating expenses.
- The company continues to expand its product portfolio.
- Executive vice president Mary K. Moreland sold 3,500 company shares on November 5, 2026.
Financial results and rising expenses
Abbott grew revenue in the third quarter of 2026 alongside rising operating expenses. Net income fell 44% to $920 million, and operating income fell 34% to $1.36 billion. Research and development expenses rose 20.1% to $920 million, while selling, general, and administrative expenses rose 39.8% to $4.3 billion. The financial results also include $100 million in additional amortization expense related to asset value adjustments for Exact Sciences.
Quarter vs the same quarter a year earlier
Portfolio development and integration of new units
The company continues to expand its product portfolio. In May 2026, Abbott received CE Mark, and in August 2026, U.S. FDA approval for the Libre Duo sensor. In August 2026, the company received CE Mark for the Amulet 360 occluder, and in September 2026, U.S. regulatory approval for the TactiFlex Duo catheter, which uses a combination of pulsed field ablation (PFA) and radiofrequency (RF) energy to treat atrial fibrillation (AFib). Also in September, it launched the SimpleScreen CRC test. For the first nine months of 2026, the integrated Exact Sciences business generated approximately $2.0 billion in revenue.
Insider transactions
Executive vice president Mary K. Moreland sold 3,500 company shares on November 5, 2026. The total value of the transaction was $406,000. Following this transaction, the executive holds 100,791 Abbott shares.
Debt load and uncertainty factors
Long-term debt increased 197.6% compared to the end of 2025, reaching $29.5 billion as of September 30, 2026. Pressure on net income may persist due to the need to amortize assets acquired in the acquisition, as the final purchase price allocation is not yet complete and may be subject to adjustments.
What to watch
Shareholders should watch future financial reports to assess the cost of servicing the $20 billion in debt raised. It is also important to monitor the release of the final purchase price allocation for Exact Sciences assets, as current estimates remain preliminary.
Original sources
- financial data (XBRL)
- 10-Q filing, November 4, 2026
- 144 filing, November 5, 2026
- 4 filing, November 6, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Abbott Laboratories
A notification in your browser or on your phone when we publish about Abbott Laboratories. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
